The U.S. government has released its 2026 Medicare Advantage and prescription drug plan quality ratings, offering insight into how major health insurers performed in providing care to seniors. These annual ratings, issued by the Centers for Medicare & Medicaid Services (CMS), play a key role in determining bonus payments to insurers—worth hundreds of millions or even billions of dollars—and influence plan revenues in 2027.
According to CMS data, CVS Health’s Aetna stands out with over 81% of members enrolled in top-rated plans, while UnitedHealth Group follows closely with 78%. Elevance Health improved significantly, reaching 55% of members in 4-star or higher plans, compared to 40% last year. In contrast, Humana saw only about 20%, or 1.2 million members, in highly rated plans.
Overall, 64% of all Medicare Advantage members with prescription drug coverage are enrolled in plans rated four stars or higher, according to Oppenheimer analysts. These ratings assess factors such as customer satisfaction, access to care, chronic disease management, and preventive health screenings, ensuring seniors can make informed choices when selecting coverage.
CVS Health said more than 63% of its Aetna Medicare Advantage members are in 4.5-star plans for next year. Meanwhile, UnitedHealth reported that 40% of its members are enrolled in 4.5-star or higher plans, consistent with its earlier projections. Analysts described this year’s results as largely expected, following recent company updates.
Centene’s Wellcare, led by CEO Michael Carson, also reported continued improvement, emphasizing the company’s focus on delivering high-quality, affordable healthcare and enhancing health outcomes nationwide.
As competition intensifies, star ratings continue to shape the landscape of the Medicare Advantage market, rewarding insurers that excel in quality and member satisfaction while motivating others to raise their standards.


Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies
Mercedes-Benz Eyes €800 Million Labor Cost Cuts in Germany
SoftBank Raises $11.1 Billion in Bond Sale to Fund OpenAI Investment
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
JPMorgan Names Lavatelli Japan Chief in Leadership Shake-Up
SMBC Eyes 20% VPBank Stake in Vietnam Expansion
Tencent Launches TenPayGo Payment App for Foreign Tourists in China
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 



